Emerging immune checkpoint blockade therapies blocking the programmed death 1 (PD-1) or its ligand PD-L1 molecules have exhibited satisfactory outcomes, with the potential to prevent the progress of advanced cancer. This evidence concerns the gene CD274 and cancer.